Fig. 2From: Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancerKaplan-Meier curves by treatment arm; advanced or metastasized lung cancer. Kaplan–Meier curves for survival by treatment arm during total observation period (55 months, 4.6 years) and median survival in months for patients with advanced or metastasized lung cancer. ICM, immune checkpoint inhibitor nivolumab, ICM-VA, therapy with immune checkpoint inhibitors and concomitant Viscum album L.; CI, confidence interval. *based on log rank testBack to article page